doi: 10.1161/CIRCGENETICS.108.828319
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Advances in Genetics, Proteomics, and Metabolomics |
Genetics of Atherothrombotic and Lacunar Stroke
From the Department of Neurology, Boston University School of Medicine and the Framingham Heart Study, Boston, Mass.
Correspondence to Sudha Seshadri, MD, Department of Neurology, Boston University School of Medicine, 72 East Concord St, B-608, Boston, MA 02118-2526. E-mail suseshad{at}bu.edu
Key Words: genes • genetics • stroke • atherothrombotic stroke • lacunar stroke
 |
Introduction |
|---|
 Top Introduction Single-Gene Disorders Causing...Genetics of Sporadic...DiscussionReferences |
|---|
Identifying new risk factors for ischemic stroke occurrence could help improve prevention strategies and identify new therapeutic targets. Genetic risk factors are particularly interesting, because they can offer a direct clue to the biological pathways involved. Ischemic stroke is a heterogeneous disorder, and this must be considered in the search for genetic susceptibility factors. In Western countries, most ischemic strokes can be attributed to large-artery atherosclerosis (atherothrombotic stroke) and small-artery occlusion (lacunar stroke), the rest being due to cardioembolism, vasculitis, monogenic disorders, undetermined causes, or rare etiologies such as cervical artery dissection. According to the Trial of Org 10172 in Acute Stroke Treatment criteria, an ischemic stroke is classified as atherothrombotic (or due to large-artery atherosclerosis) if it is associated with a >50% stenosis of an appropriate intracranial or extracranial artery1 and as lacunar (typically due to lipohyalinosis and microatheroma) if a brain stem or subcortical infarct of
1.5-cm diameter can be demonstrated and large-artery atherosclerosis and cardioembolism can be excluded.1 In the present study, we reviewed published data on the genetic risk factors underlying atherothrombotic and lacunar strokes. Our reasons for focusing on these 2 subtypes are that (1) extensive reviews exploring the genetic risk factors for total ischemic stroke already exist,2–4 (2) there is some evidence that genetic susceptibility factors may differ according to stroke subtype, and (3) atherothrombotic and lacunar stroke may have a greater genetic component than cardioembolic stroke.5–7
|
Single-Gene Disorders Causing Atherothrombotic and Lacunar Stroke |
|---|
|
TopIntroductionSingle-Gene Disorders Causing...Genetics of Sporadic...DiscussionReferences |
|---|
Several monogenic disorders can cause large-artery and small-vessel stroke. Overall, they are responsible for a very small proportion of these strokes, probably <1%,8 and should mainly be considered when stroke occurs at a young age in individuals with little or no exposure to conventional vascular risk factors. The mechanisms by which these monogenic disorders result in stroke are varied.
Cerebral Autosomal Dominant Arteriopathy, Subcortical Infarcts, and Leukoencephalopathy
Cerebral autosomal dominant arteriopathy, subcortical infarcts and leukoencephalopathy is a rare autosomal dominant disease caused by mutations in the Notch3 gene on chromosome 19.9 Notch3 encodes a cell-surface receptor involved in vascular smooth muscle cell survival and vascular remodeling. The prevalence of this disorder has been estimated at 
1 of 24 000, which is probably an underestimation (www.orpha.net). Patients with cerebral autosomal dominant arteriopathy, subcortical infarcts and leukoencephalopathy suffer from recurrent lacunar strokes. The phenotype also includes progressive cognitive impairment, psychiatric disturbances—especially mood disturbances—and migraine with aura, with an onset between the third and sixth decade. The underlying vascular lesion is a nonarteriosclerotic, amyloid-negative angiopathy involving small arteries and capillaries.10 The definitive diagnostic test is the molecular genetic analysis of the Notch3 gene. Skin biopsy can reveal characteristic granular osmiophilic material within the vascular basal lamina on electron microscopic examination.11 So far, only symptomatic treatments are available.
Sickle Cell Disease
Sickle cell disease is an autosomal recessive disease, which can be due to either a homozygous state for hemoglobin S (HbS) or to the combined heterozygous state with other hemoglobinopathies, such as hemoglobin C (HbC) or mild β-thalassemia.12 HbS results from a mutation on the hemoglobin-β (HBB) gene on chromosome 11, which is present on 3 African haplotypes and a fourth Arab Indian haplotype.12 The prevalence of the disease at birth varies in affected populations between 0.02% and 3% (www.orpha.net). Stroke affects up to 25% of patients aged 45 years and includes both large-artery and small-vessel ischemic stroke (with a peak incidence in early childhood) and hemorrhagic stroke (mainly in adults).13 Large-artery strokes are due to intimal thickening, fibroblast and smooth muscle cell proliferation, and thrombus formation, mainly in the distal internal carotid artery and the proximal middle and anterior cerebral arteries.10,12 Small-vessel strokes are probably caused by sludging and intravascular sickling in smaller vessels. Other clinical features include vaso-occlusive or painful crisis, retinopathy, chronic leg ulcers, and increased susceptibility to infection.12 Transfusion therapy can reduce the risk of stroke.
Homocysteinuria
Homocysteinuria includes several heritable, mainly autosomal recessive, diseases causing elevated plasma concentrations of homocysteine and homocysteinuria. The most frequent cause is a mutation in the cystathionine β-synthase (CBS) gene on chromosome 21. On the basis of data from newborn screening, the rate of occurrence of homocysteinuria is 1 of 344 000 (www.orpha.net), but prevalence rates of up to 1 of 20 500 have been described in some European countries.14 Thromboembolism is a key clinical feature affecting large and small arteries, and veins. The chances of suffering a thromboembolic event were estimated at 25% by age 16 and 50% by age 29, more than half of these events being venous and 32% cerebrovascular.15 Other clinical features include ectopia lentis, mental retardation, and osteoporosis. Ischemic stroke in homocysteinuria has been primarily attributed to accelerated atherosclerosis.16 However, some pathological studies suggest that arterial damage in homocysteinuria differs from atherosclerosis, most notably by a lack of lipid deposition.17 Other mechanisms could include endothelium-mediated thrombosis through direct toxicity of homocysteine on the endothelium.17 Isolated cases of cervical artery dissection have also been reported.18 Treatments to lower plasma homocysteine levels and stroke risk include pyridoxine, methionine-restricted diet, folate and vitamin B12 supplementation, and betaine.
Fabry Disease
Fabry disease is an X-linked disease caused by a mutation in the galactosidase-
(GLA) gene. Women heterozygous for the mutation can also be symptomatic but are usually less severely affected than men. The incidence of the disease is estimated at 1 of 40 000 (www.orpha.net). In a large survey of young patients with cryptogenic ischemic stroke, 4% carried a mutation in GLA.19 Ischemic stroke can be due to both small- and large-vessel disease, with a predominance in the vertebro-basilar circulation.19 Deposition of globotriaosylceramide in the vascular wall and dolichectasia of the basilar and vertebral arteries have been described,10 but the mechanisms underlying stroke are still poorly understood. Clinical features include acroparesthesiae, angiokeratomas, and hypohidrosis, which often develop in childhood or adolescence, before systemic complications leading to strokes, heart failure, and chronic kidney disease occur. The diagnosis is made by measuring -galactosidase A activity or by mutation screening, the former being less reliable in women. Enzyme-replacement therapy was recently shown to improve some symptoms, but the effect on stroke prevention remains unclear.20
Interestingly, recent studies suggest that polymorphisms in other genes can influence the phenotypic expression of these monogenic diseases. In sickle cell disease, in particular, the risk of stroke was shown to be substantially influenced by a variety of modifier genes.21 However, there is no data on whether these modifier genes differentially affect the risk of specific subtypes of ischemic stroke. One of the suggested modifier genes of stroke risk in sickle cell disease, selectin P (SELP),21 was also studied in relation with sporadic lacunar and atherothrombotic stroke, but no significant association was observed (Supplemental Table XII).
|
Genetics of Sporadic Atherothrombotic and Lacunar Stroke |
|---|
|
TopIntroductionSingle-Gene Disorders Causing...Genetics of Sporadic...DiscussionReferences |
|---|
Importance of Genetic Factors in Apparently Sporadic Atherothrombotic and Lacunar Stroke
There is an evidence in the literature, both from twin studies22 and from studies on the family history of stroke5,23,24 that genetic factors substantially contribute to stroke susceptibility. However, the influence of family history on stroke risk remains controversial, with some studies describing no impact of parental history on stroke risk.25 Reasons for these inconsistencies may be (1) difficulty in reliably assessing parental stroke status, (2) late occurrence of stroke (parents with a genetic predisposition to stroke may have died of alternative causes before they developed a stroke), and (3) the heterogeneity of stroke, which only some studies have accounted for. Many studies combined ischemic and hemorrhagic stroke and only a few studies considered ischemic stroke subtypes.25 In 4 hospital-based series where patients with ischemic stroke were compared with healthy controls, family history of stroke was found to be independently associated with an increased risk of large-artery stroke (odds ratio [OR], 1.88 [95% CI, 1.02 to 3.44] to 2.24 [1.49 to 3.36]) and small-vessel stroke (OR, 1.79 [1.13 to 2.84] to 2.76 [1.55 to 4.91]), the association with cardioembolic stroke being much weaker.5–7,26 Other studies could not demonstrate any association,27 or only showed a trend toward an increased frequency of positive family history in persons with a lacunar stroke28 and decreased frequency in cardioembolic stroke,29 but these studies did not include a control population and were probably underpowered.
Assuming that a positive family history is a marker of increased genetic risk, this risk is expected to be higher in stroke subtypes that are more strongly associated with a positive family history. Thus, the sample size needed to unravel genetic effects is probably smaller when focusing on these subtypes.6 Moreover, certain genetic factors probably predispose to specific subtypes of ischemic stroke only, and not to ischemic stroke overall.6 Focusing on ischemic stroke subtypes for which a stronger genetic component is suspected may therefore be a key element in elucidating the genetic contribution to ischemic stroke. Genetic variants could act at various levels (eg, by increasing the risk of and susceptibility to "conventional" stroke risk factors such as hypertension or diabetes) by influencing specific mechanisms underlying stroke, such as the occurrence and progression of atherosclerosis or lipohyalinosis, by predisposing to arterial thrombosis, or by modifying tolerance to brain ischemia.3 The underlying genetic model is expected to be multifactorial, involving several genetic polymorphisms that each confer small increases in risk, with ORs almost always below 1.5 and usually 1.1 to 1.3.30,31 A number of approaches have been used to determine the underlying genetic variants contributing to sporadic ischemic stroke risk, including (1) candidate gene association studies, (2) genome-wide association studies (GWAS), and (3) linkage studies.
Search Strategy
References for this second part of the review were identified through searches of PubMed from 1966 to July 1, 2008, with the terms: gene [MeSH], polymorphism, genetic [MeSH], haplotypes [MeSH], genetic markers [MeSH], linkage (genetics), mutation [MeSH], genetic predisposition to disease, sequence analysis, DNA [MeSH], genotype [MeSH], alleles [MeSH], brain infarction [MeSH], and stroke [MeSH]. We selected only articles that had specific data on genetic variation underlying "all stroke" and "ischemic stroke," after perusal of all titles, abstracts, and, where necessary, the complete article. We further narrowed our selection to include only articles with pertinent information on the atherothrombotic and/or lacunar subtypes of ischemic stroke. Details on the selection criteria are provided in a methodologic online supplement.
Candidate-Gene Association Studies
Candidate-gene association studies test the association of a disease with genetic variants selected through a priori hypotheses about the underlying pathophysiology; typically, they use a case-control study design. We identified 133 candidate-gene association studies that included data on atherothrombotic and lacunar ischemic stroke subtypes and satisfied our inclusion criteria. Data from all these studies are summarized in the online Appendix as a series of 12 Supplemental Tables. Each table summarizes data related to a single etiopathologic pathway. For each study, we describe the gene and specific polymorphism studied, the ethnic composition and size of the study sample, the stroke subtype classification system used, and the number of atherothrombotic and lacunar stroke events. For studies that found an association, the ORs and 95% confidence intervals were reported.
Renin-Angiotensin System
The insertion/deletion polymorphism in intron 16 of the angiotensin-converting enzyme (ACE) gene is one of the most frequently studied genetic variations in relation to atherosclerosis and vascular disease. ACE converts angiotensin I to the vasoconstrictor angiotensin II and inactivates the vasodilator bradykinin, thus contributing to the regulation of vascular tone, endothelial function, and smooth muscle cell proliferation. The insertion/deletion polymorphism in the ACE gene was significantly associated with lacunar stroke in 3 independent populations, with an increased risk for D-allele carriers.32–34 However, 9 other studies found no association of this variant with lacunar stroke.35–43 None of the studies found an association of the ACE insertion/deletion variant with atherothrombotic stroke, and other ACE variants were associated neither with atherothrombotic nor with lacunar stroke (supplemental Table I).
Inflammatory System
Inflammation is a key process in atherosclerosis and therefore stroke and coronary heart disease. Leukotrienes are potent proinflammatory molecules, which are involved in leukocyte recruitment and adhesion to the vascular endothelium, as well as in endothelial cell permeability and vascular smooth muscle cell migration.44 One genetic variant (rs730012) in the leukotriene C4 synthase (LTC4S) gene was found to be associated with lacunar stroke in 2 different populations, with an increased risk for A-allele carriers.44 Interleukin (IL)-6 is a pleiotropic cytokine that inhibits the production of potent proinflammatory cytokines, such as tumor necrosis factor- and IL-1.45 Increased levels of IL-6 in the plasma and cerebrospinal fluid were shown to correlate with infarct size and functional outcome of patients with stroke.45 One genetic variant (rs1800795) in the IL-6 gene was associated with lacunar stroke in 2 different populations, with an increased risk for CC-homozygotes,45,46 but it is not clear whether the samples in these 2 studies overlap, and a third study found no association.47 Two studies found an association of atherothrombotic stroke with 2 different variants in the IL-6 gene (rs1800796 and rs1800795),47,48 but these associations were not confirmed.46 None of the other associations described in single studies, between lacunar stroke and variants in CD14, IL-1β, TGFB1, and tumor necrosis factor, or between atherothrombotic stroke and variants in LTA and LTC4S, were replicated (supplemental Table II).
Thrombosis and Hemostasis
Platelet glycoprotein receptors are members of the integrin family, which, when activated, bind fibrinogen, von Willebrand factor, or collagen, and hence promote platelet aggregation and thrombosis.3 An increased risk of atherothrombotic stroke was found in A2-allele carriers of the integrin β-3 (ITGB3 or GPIIIa) P1(A1/A2) variant (rs5918) in 3 independent populations.49–51 However, 3 other studies did not find any association between atherothrombotic stroke and this variant,52–54 or found such an association only in subgroups of patients.52 Factor XIII catalyzes the formation of covalent bounds between fibrin monomers, which stabilizes the fibrin clot, and is also involved in the cross-linking of -2 antiplasmin, fibronectin, and collagen.55 Two studies found an increased risk of atherothrombotic stroke associated with the Val/Val genotype of rs5985 in F13A1 (coagulation factor XIII, A1 polypeptide),55,56 but 2 other studies found no association.57,58 None of the other associations noted, between lacunar stroke and variants in F13A1, GP1BA, CPB2, and PLAT, or between atherothrombotic stroke and variants in F5, F12, FGB, ITGA, and CPB2, could be consistently replicated (supplemental Table III).
Lipid Metabolism
Individuals with increased plasma cholesterol, especially low-density lipoprotein, levels are at a higher risk of premature atherosclerosis. Thus, genes encoding proteins involved in plasma lipoprotein metabolism are interesting candidates when looking for genetic risk factors of ischemic stroke. The epsilon polymorphism in exon 4 of the gene-encoding apolipoprotein E (APOE), which plays a key role in lipoprotein transport, has been extensively studied in relation with atherosclerosis and vascular events. An increased risk of atherothrombotic stroke was found for APOE 
4 carriers in 5 different studies (compared with noncarriers or to 3 homozygotes),32,59–62 but in 1 other study the association was in the opposite direction,63 and 5 studies did not find any association.40,48,64–66 One study also observed an increased risk of atherothrombotic stroke in patients with 2/2 or 2/3 genotypes.62 In a meta-analysis including a portion of the data from these studies, no significant association was observed between APOE and either lacunar or atherothrombotic stroke.67 Paraoxonase 1 (PON1) prevents lipid peroxidation of low-density lipoproteins, an important early step in the atherosclerosis process. Knockout mice lacking PON1 were shown to have an increased susceptibility to atherosclerosis, and lowered PON1 activity was observed in vascular disease.68 Two studies found an increased risk of atherothrombotic stroke for carriers of the R allele or the RR genotype of rs662 in PON1,68,69 but 3 other studies did not find any association.48,70,71 The associations between lacunar stroke and variants in APOA5 or between atherothrombotic stroke and variants in ABCA1, LPA, APOA5, EPHX2, LPL, PON2, and PON3 have not been replicated (supplemental Table IV).
Endothelial Function and Oxidative Stress
Several studies have suggested that mild to moderate elevations of serum homocysteine are associated with increased risk of vascular disease. Homocysteine levels tend to be higher in individuals homozygous for the thermolabile variant of the methylene tetrahydrofolate reductase (MTHFR) gene, due to a C-to-T transition at position 677. Four studies found an increased risk of atherothrombotic stroke in carriers of the TT genotype of the 677C>T variant in MTHFR,48,72–74 but 7 other studies did not find any association.32,40,72,75–78 In a meta-analysis, no association was found with the lacunar and atherothombotic stroke subtypes.79 None of the associations between lacunar stroke and variants in NOS3, MTHFR, or CYBA, or between atherothrombotic stroke and variants in NOS3 and CYBA, were consistently replicated (supplemental Table V).
Genes Identified Through Linkage Analysis in an Icelandic Population
The DECODE group in Iceland first demonstrated linkage of stroke with the 5q12 locus using a genome-wide linkage approach80 and subsequently identified an association of stroke with genetic variants in the phosphodiesterase 4D (PDE4D) gene within this locus.81 The same group also identified significant linkage of myocardial infarction with the 13q12–13 locus, and a significant association of both myocardial infarction and stroke with variants in the arachidonate 5-lipoxygenase-activating protein (ALOX5AP) gene within this second locus.82 Several studies subsequently looked for an association of genetic variants in these 2 genes with stroke. Two studies found an increased risk of atherothrombotic stroke for carriers of the rare variant of SNP83 (rs966221) in PDE4D,81,83 but 4 other studies could not replicate this finding.84–87 None of the other associations of PDE4D and none of the associations of ALOX5AP with the lacunar and atherothrombotic stroke subtypes have been consistently replicated. In a recent meta-analysis, a borderline significant association of lacunar stroke with PDE4D SNP89 was observed (OR, 0.79 [0.62 to 1.00]; P=0.05), which became nonsignificant when the analysis was restricted to whites (Supplemental Table VI).88
Other Pathways
None of the associations of lacunar stroke with variants in CTSG, PRKCH, and mitochondrial DNA, or of atherothrombotic stroke with variants in NPY, HSPA1B, or mitochondrial DNA, have been replicated (supplemental Table VII).
Other genes that have been tested, but for which no association was found in any of the published studies, are presented in supplemental Tables VIII through XII.
GWAS
GWAS explore the genetic risk factors underlying a condition by genotyping a large number (100 000 to 1 000 000) of single nucleotide polymorphisms (SNPs) that are distributed across the chromosomes; they assume no a priori hypothesis regarding genomic loci of interest. They have been applied to a number of complex diseases with several notable successes, eg, the identification of previously unsuspected genes conferring an increased risk of diabetes31 and coronary heart disease.89 So far, only 1 GWAS has been published on ischemic stroke.90 This study compared 408 803 SNPs in 249 white patients with ischemic stroke and 268 white controls, using the Illumina Infinium Human-1 and HumanHap300 SNP chips (Illumina Inc, San Diego, Calif). None of the polymorphisms reached the threshold for genome-wide significance, for ischemic stroke overall and for all ischemic stroke subtypes. However, the statistical power of this pilot study was insufficient to detect small size effects (OR <1.5), especially for rarer genetic variants.90 Noteworthy, in the genome-wide analysis for large- and small-artery ischemic stroke, none of the SNPs with the lowest probability values (<10–4) was located in any of the previously reported candidate genes.90
Linkage Studies
Linkage studies are family based and test whether genetic markers cosegregate with a given disease within families. They have been used successfully to identify genes underlying monogenic forms of ischemic stroke, such as cerebral autosomal dominant arteriopathy, subcortical infarcts and leukoencephalopathy,9 but they are less powerful when the pattern of inheritance is not mendelian,91 which is true for most ischemic strokes.
Two genome-wide linkage studies on sporadic ischemic stroke have been published.80,92 The first study used a multipoint, affected-only allele-sharing method in 476 patients with stroke and 438 of their relatives, and found strong evidence for linkage with a logarithm of odds score of 4.86 on chromosome 5q12 for ischemic stroke.80 When ischemic stroke subtypes were investigated, the logarithm of odds scores were still positive but smaller than those observed in the overall analysis, consistent with a loss of power because of the smaller sample sizes (detailed results were not published). The second study did not identify any new stroke locus and did not report linkage analyses for ischemic stroke subtypes.92 Other studies that attempted to replicate the genetic linkage with the chromosome 5 locus did not report results on ischemic stroke subtypes.83,93
|
Discussion |
|---|
|
TopIntroductionSingle-Gene Disorders Causing...Genetics of Sporadic...DiscussionReferences |
|---|
Although they represent only a limited proportion of the published genetic association studies on ischemic stroke, a substantial number of studies have looked for genetic risk factors underlying lacunar and atherothrombotic stroke. Most of these studies were negative. Several significant associations that were described were not replicated in independent populations. Only a very small number of associations were found in at least 2 independent samples: these are associations of lacunar stroke with ACE32–34 and LTC4S45,46 variants, and of atherothrombotic stroke with ITGB3,49–51 F13A1,55,56 APOE,32,59–63 PON1,68,69 MTHFR,48,72,73 and PDE4D81,83 variants. For most of these associations, there are also negative studies that were published, so that even these remain controversial. Interestingly, in most instances genetic associations differed between lacunar and atherothrombotic stroke, which supports the notion that their genetic backgrounds are distinct.
Limitations
Published studies on the genetic risk factors for sporadic atherothrombotic and lacunar stroke suffer from limitations that are similar to those of most genetic association studies on stroke,94 and most candidate gene association studies in general.30,94 The 2 main limitations are (1) the lack of replication in independent samples of the vast majority of positive associations and (2) the insufficient statistical power of most studies to detect modest associations.30,94 The sample sizes needed to achieve a statistical power 
80% (assuming an additive genetic model, and a type I error rate <0.05) can be estimated at 267 cases, and the same number of controls for a SNP with a minor (rare) allele frequency of 20% and an OR1.5 (http://pngu.mgh.harvard.edu/
purcell/gpc/). This number increases to 385 and 646 for ORs of 1.3 and 1.1, respectively. If the minor allele frequency is 10%, the numbers become 455, 843, and 2372. Among the studies reviewed here, most had <100 subjects per group.
Other limitations are more specific to the study of stroke subtypes. Most studies tested the association of genetic variants with several ischemic stroke subtypes in a secondary analysis, and only a few of them adjusted for multiple testing, thus leading potentially to spurious associations. Moreover, the variation in the criteria used to define ischemic stroke subtypes may lead to substantial heterogeneity in the phenotype definition.95 This may have either diluted real effects of genetic variants or may lead to nonspecific associations, and thus could explain contradictory findings between studies. Some studies used mechanistic subtyping systems (such as the Classification of Cerebrovascular Diseases III,96 International Classification of Diseases, or Trial of Org 10172 in Acute Stroke Treatment1 system), which classify stroke on the basis of inferred origin of cerebrovascular occlusion.95 Other studies used systems based on clinical presentation or location and size of the lesion within the brain (such as the Oxfordshire Community Stroke Project system97) that are practical, but may result in less homogenous categorization of stroke subtypes from a mechanistic point of view.
In this review, we have not addressed the genetic variation in copy number, telomeric length, or epigenetic mechanisms as possible explanations for the observed heritability of stroke risk. Finally, although efforts were made to be comprehensive in the retrieval of studies, it is possible that relevant studies were inadvertently missed.
Future Directions
There is an urgent need for large genetic association studies designed specifically to look for genetic risk factors underlying ischemic stroke subtypes. The atherothrombotic and lacunar subtypes are particularly important because they are the most frequent causes of ischemic stroke and because there is some evidence that they have a stronger genetic component than other ischemic stroke subtypes.5–7 The genotyping of large numbers of well-phenotyped patients, defined according to standardized and validated mechanistic classification systems, will require large collaborative efforts, such as the International Stroke Genetics Consortium (www.strokegenetics.org), the Cohorts for Heart and Aging Research in Genetic Epidemiology consortium, or the Candidate Gene Association Resource.98
Genetic marker selection can be improved by studying several SNPs and haplotypes instead of single markers on a given gene to account for possible allelic variation between individuals and ethnic groups and by simultaneously studying several genes in the same pathway instead of a single gene, with adequate correction for multiple testing. GWAS offer a promising alternative, permitting an unbiased approach, without any a priori assumptions regarding the underlying pathophysiology. Preplanned replication of positive findings is highly recommended. Emerging statistical and bioinformatic techniques that improve our ability to study gene-gene and gene-environment interactions may assist in uncovering novel genetic variation underlying stroke risk.
Genetic association studies on intermediate phenotypes of atherothrombotic and lacunar stroke, such as carotid intima-media thickness and plaques, or white matter hyperintensities on brain MRI, could also help identify genetic susceptibility factors to these stroke subtypes. Indeed, these intermediate traits are highly heritable, quantitative, and can be assessed noninvasively in large population samples, thus increasing the statistical power to detect associations. Several candidate gene studies on these intermediate phenotypes have been published,99,100 and GWAS analyses are under way. Validation of these associations in case-control studies of ischemic stroke patients will, however, still be required.
Noteworthy, genetic association studies on total ischemic stroke remain scientifically valid, because some genes may be associated with pathophysiological mechanisms common to all ischemic strokes, such as susceptibility to ischemia. Thus, large and well-designed genetic association studies of ischemic stroke in general and ischemic stroke subtypes should contribute substantially in the near future to a better understanding of the pathophysiology underlying ischemic stroke. These discoveries may permit the identification of new therapeutic targets aimed at stroke prevention and neuroprotection from ischemic injury.
|
Acknowledgments |
|---|
Sources of Funding
This work was supported by the National Heart, Lung, and Blood Institute’s Framingham Heart Study (NIH/NHLBI contract N01-HC-25195) and grants from the National Institute of Neurological Disorders and Stroke (NS17950) and the National Institute of Aging (AG08122, AG16495 [Principal Investigator: Philip A. Wolf], and AG033193 [Principal Investigator: Sudha Seshadri]). Dr Debette is supported by a Fulbright grant and received an award from the Lilly Institute.
Disclosures
None.
|
Footnotes |
|---|
Guest Editor for this article was Donna K. Arnett, PhD.
The online-only Data Supplement is available at http://circgenetics.ahajournals.org/cgi/content/full/2/2/191/DC1.
|
References |
|---|
|
TopIntroductionSingle-Gene Disorders Causing...Genetics of Sporadic...DiscussionReferences |
|---|
1. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE III. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993; 24: 35–41.
2. Bersano A, Ballabio E, Bresolin N, Candelise L. Genetic polymorphisms for the study of multifactorial stroke. Hum Mutat. 2008; 29: 776–795.[CrossRef][Medline]
3. Hassan A, Markus HS. Genetics and ischaemic stroke. Brain. 2000; 123 (Pt 9): 1784–1812.
4. Dichgans M. Genetics of ischaemic stroke. Lancet Neurol. 2007; 6: 149–161.[CrossRef][Medline]
5. Jood K, Ladenvall C, Rosengren A, Blomstrand C, Jern C. Family history in ischemic stroke before 70 years of age: the sahlgrenska academy study on ischemic stroke. Stroke. 2005; 36: 1383–1387.
6. Jerrard-Dunne P, Cloud G, Hassan A, Markus HS. Evaluating the genetic component of ischemic stroke subtypes: a family history study. Stroke. 2003; 34: 1364–1369.
7. Polychronopoulos P, Gioldasis G, Ellul J, Metallinos IC, Lekka NP, Paschalis C, Papapetropoulos T. Family history of stroke in stroke types and subtypes. J Neurol Sci. 2002; 195: 117–122.[CrossRef][Medline]
8. Leys D, Bandu L, Henon H, Lucas C, Mounier-Vehier F, Rondepierre P, Godefroy O. Clinical outcome in 287 consecutive young adults (15 to 45 years) with ischemic stroke. Neurology. 2002; 59: 26–33.
9. Joutel A, Corpechot C, Ducros A, Vahedi K, Chabriat H, Mouton P, Alamowitch S, Domenga V, Cecillion M, Marechal E, Maciazek J, Vayssiere C, Cruaud C, Cabanis EA, Ruchoux MM, Weissenbach J, Bach JF, Bousser MG, Tournier-Lasserve E. Notch3 mutations in cadasil, a hereditary adult-onset condition causing stroke and dementia. Nature. 1996; 383: 707–710.[CrossRef][Medline]
10. Dichgans M. Monogenic causes of ischemic stroke. In: Markus H, ed. Stroke Genetics. Oxford, United Kingdom: Oxford University Press; 2003.
11. Ruchoux MM, Chabriat H, Bousser MG, Baudrimont M, Tournier-Lasserve E. Presence of ultrastructural arterial lesions in muscle and skin vessels of patients with cadasil. Stroke. 1994; 25: 2291–2292.[Medline]
12. Stuart MJ, Nagel RL. Sickle-cell disease. Lancet. 2004; 364: 1343–1360.[CrossRef][Medline]
13. Ohene-Frempong K, Weiner SJ, Sleeper LA, Miller ST, Embury S, Moohr JW, Wethers DL, Pegelow CH, Gill FM. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood. 1998; 91: 288–294.
14. Gaustadnes M, Ingerslev J, Rutiger N. Prevalence of congenital homocystinuria in Denmark. N Engl J Med. 1999; 340: 1513.
15. Mudd SH, Skovby F, Levy HL, Pettigrew KD, Wilcken B, Pyeritz RE, Andria G, Boers GH, Bromberg IL, Cerone R. The natural history of homocystinuria due to cystathionine beta-synthase deficiency. Am J Hum Genet. 1985; 37: 1–31.[Medline]
16. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med. 1998; 338: 1042–1050.
17. Bellamy MF, McDowell IF. Putative mechanisms for vascular damage by homocysteine. J Inherit Metab Dis. 1997; 20: 307–315.[CrossRef][Medline]
18. Kelly PJ, Furie KL, Kistler JP, Barron M, Picard EH, Mandell R, Shih VE. Stroke in young patients with hyperhomocysteinemia due to cystathionine beta-synthase deficiency. Neurology. 2003; 60: 275–279.
19. Rolfs A, Bottcher T, Zschiesche M, Morris P, Winchester B, Bauer P, Walter U, Mix E, Lohr M, Harzer K, Strauss U, Pahnke J, Grossmann A, Benecke R. Prevalence of fabry disease in patients with cryptogenic stroke: a prospective study. Lancet. 2005; 366: 1794–1796.[CrossRef][Medline]
20. Schiffmann R, Kopp JB, Austin HA III, Sabnis S, Moore DF, Weibel T, Balow JE, Brady RO. Enzyme replacement therapy in fabry disease: a randomized controlled trial. JAMA. 2001; 285: 2743–2749.
21. Sebastiani P, Ramoni MF, Nolan V, Baldwin CT, Steinberg MH. Genetic dissection and prognostic modeling of overt stroke in sickle cell anemia. Nat Genet. 2005; 37: 435–440.[CrossRef][Medline]
22. Bak S, Gaist D, Sindrup SH, Skytthe A, Christensen K. Genetic liability in stroke: a long-term follow-up study of danish twins. Stroke. 2002; 33: 769–774.
23. Kiely DK, Wolf PA, Cupples LA, Beiser AS, Myers RH. Familial aggregation of stroke. The Framingham Study. Stroke. 1993; 24: 1366–1371.
24. Liao D, Myers R, Hunt S, Shahar E, Paton C, Burke G, Province M, Heiss G. Familial history of stroke and stroke risk. The Family Heart Study. Stroke. 1997; 28: 1908–1912.
25. Flossmann E, Schulz UG, Rothwell PM. Systematic review of methods and results of studies of the genetic epidemiology of ischemic stroke. Stroke. 2004; 35: 212–227.
26. Lee TH, Hsu WC, Chen CJ, Chen ST. Etiologic study of young ischemic stroke in Taiwan. Stroke. 2002; 33: 1950–1955.
27. Meschia JF, Brown RD Jr, Brott TG, Hardy J, Atkinson EJ, O'Brien PC. Feasibility of an affected sibling pair study in ischemic stroke: results of a 2-center family history registry. Stroke. 2001; 32: 2939–2941.
28. Lisabeth LD, Smith MA, Brown DL, Uchino K, Morgenstern LB. Family history and stroke outcome in a bi-ethnic, population-based stroke surveillance study. BMC Neurol. 2005; 5: 20.[CrossRef][Medline]
29. Schulz UG, Flossmann E, Rothwell PM. Heritability of ischemic stroke in relation to age, vascular risk factors, and subtypes of incident stroke in population-based studies. Stroke. 2004; 35: 819–824.
30. Zondervan KT, Cardon LR. Designing candidate gene and genome-wide case-control association studies. Nat Protoc. 2007; 2: 2492–2501.[CrossRef][Medline]
31. Zeggini E, Scott LJ, Saxena R, Voight BF, Marchini JL, Hu T, de Bakker PI, Abecasis GR, Almgren P, Andersen G, Ardlie K, Bostrom KB, Bergman RN, Bonnycastle LL, Borch-Johnsen K, Burtt NP, Chen H, Chines PS, Daly MJ, Deodhar P, Ding CJ, Doney AS, Duren WL, Elliott KS, Erdos MR, Frayling TM, Freathy RM, Gianniny L, Grallert H, Grarup N, Groves CJ, Guiducci C, Hansen T, Herder C, Hitman GA, Hughes TE, Isomaa B, Jackson AU, Jorgensen T, Kong A, Kubalanza K, Kuruvilla FG, Kuusisto J, Langenberg C, Lango H, Lauritzen T, Li Y, Lindgren CM, Lyssenko V, Marvelle AF, Meisinger C, Midthjell K, Mohlke KL, Morken MA, Morris AD, Narisu N, Nilsson P, Owen KR, Palmer CN, Payne F, Perry JR, Pettersen E, Platou C, Prokopenko I, Qi L, Qin L, Rayner NW, Rees M, Roix JJ, Sandbaek A, Shields B, Sjogren M, Steinthorsdottir V, Stringham HM, Swift AJ, Thorleifsson G, Thorsteinsdottir U, Timpson NJ, Tuomi T, Tuomilehto J, Walker M, Watanabe RM, Weedon MN, Willer CJ, Illig T, Hveem K, Hu FB, Laakso M, Stefansson K, Pedersen O, Wareham NJ, Barroso I, Hattersley AT, Collins FS, Groop L, McCarthy MI, Boehnke M, Altshuler D. Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nat Genet. 2008; 40: 638–645.[CrossRef][Medline]
32. Szolnoki Z, Somogyvari F, Kondacs A, Szabo M, Fodor L. Evaluation of the interactions of common genetic mutations in stroke subtypes. J Neurol. 2002; 249: 1391–1397.[CrossRef][Medline]
33. Hong SH, Park HM, Ahn JY, Kim OJ, Hwang TS, Oh D, Kim NK. Ace I/D polymorphism in Korean patients with ischemic stroke and silent brain infarction. Acta Neurol Scand. 2008; 117: 244–249.[CrossRef][Medline]
34. Markus HS, Barley J, Lunt R, Bland JM, Jeffery S, Carter ND, Brown MM. Angiotensin-converting enzyme gene deletion polymorphism. A new risk factor for lacunar stroke but not carotid atheroma. Stroke. 1995; 26: 1329–1333.
35. Catto A, Carter AM, Barrett JH, Stickland M, Bamford J, Davies JA, Grant PJ. Angiotensin-converting enzyme insertion/deletion polymorphism and cerebrovascular disease. Stroke. 1996; 27: 435–440.
36. Dikmen M, Gunes HV, Degirmenci I, Ozdemir G, Basaran A. Are the angiotensin-converting enzyme gene and activity risk factors for stroke? Arq Neuropsiquiatr. 2006; 64: 211–216.[Medline]
37. Doi Y, Yoshinari M, Yoshizumi H, Ibayashi S, Wakisaka M, Fujishima M. Polymorphism of the angiotensin-converting enzyme (ACE) gene in patients with thrombotic brain infarction. Atherosclerosis. 1997; 132: 145–150.[CrossRef][Medline]
38. Pera J, Slowik A, Dziedzic T, Wloch D, Szczudlik A. Ace I/D polymorphism in different etiologies of ischemic stroke. Acta Neurol Scand. 2006; 114: 320–322.[CrossRef][Medline]
39. Tuncer N, Tuglular S, Kilic G, Sazci A, Us O, Kara I. Evaluation of the angiotensin-converting enzyme insertion/deletion polymorphism and the risk of ischaemic stroke. J Clin Neurosci. 2006; 13: 224–227.[CrossRef][Medline]
40. Gao X, Yang H, ZhiPing T. Association studies of genetic polymorphism, environmental factors and their interaction in ischemic stroke. Neurosci Lett. 2006; 398: 172–177.[CrossRef][Medline]
41. Lin JJ, Yueh KC, Lin GY, Chang DC, Chang CY, Shieh HL, Harn HJ. Lack of association between angiotensin i-converting enzyme gene deletion polymorphism and cerebrovascular disease in Taiwanese. J Formos Med Assoc. 2000; 99: 895–901.[Medline]
42. Pullicino P, Kwen PL, Greenberg S, Becker AL, Glenister N. Angiotensin-converting enzyme gene and lacunar stroke. Stroke. 1996; 27: 569–570.[Medline]
43. Ueda S, Weir CJ, Inglis GC, Murray GD, Muir KW, Lees KR. Lack of association between angiotensin converting enzyme gene insertion/deletion polymorphism and stroke. J Hypertens. 1995; 13: 1597–1601.[Medline]
44. Bevan S, Dichgans M, Wiechmann HE, Gschwendtner A, Meitinger T, Markus HS. Genetic variation in members of the leukotriene biosynthesis pathway confer an increased risk of ischemic stroke: a replication study in two independent populations. Stroke. 2008; 39: 1109–1114.
45. Revilla M, Obach V, Cervera A, Davalos A, Castillo J, Chamorro A. A -174G/C polymorphism of the interleukin-6 gene in patients with lacunar infarction. Neurosci Lett. 2002; 324: 29–32.[CrossRef][Medline]
46. Chamorro A, Revilla M, Obach V, Vargas M, Planas AM. The -174G/C polymorphism of the interleukin 6 gene is a hallmark of lacunar stroke and not other ischemic stroke phenotypes. Cerebrovasc Dis. 2005; 19: 91–95.[Medline]
47. Greisenegger S, Endler G, Haering D, Schillinger M, Lang W, Lalouschek W, Mannhalter C. The (-174) G/C polymorphism in the interleukin-6 gene is associated with the severity of acute cerebrovascular events. Thromb Res. 2003; 110: 181–186.[CrossRef][Medline]
48. Yamada Y, Metoki N, Yoshida H, Satoh K, Ichihara S, Kato K, Kameyama T, Yokoi K, Matsuo H, Segawa T, Watanabe S, Nozawa Y. Genetic risk for ischemic and hemorrhagic stroke. Arterioscler Thromb Vasc Biol. 2006; 26: 1920–1925.
49. Streifler JY, Rosenberg N, Chetrit A, Eskaraev R, Sela BA, Dardik R, Zivelin A, Ravid B, Davidson J, Seligsohn U, Inbal A. Cerebrovascular events in patients with significant stenosis of the carotid artery are associated with hyperhomocysteinemia and platelet antigen-1 (leu33pro) polymorphism. Stroke. 2001; 32: 2753–2758.
50. Szolnoki Z, Somogyvari F, Kondacs A, Szabo M, Bene J, Havasi V, Komlosi K, Melegh B. Increased prevalence of platelet glycoprotein IIb/IIIa PLA2 allele in ischaemic stroke associated with large vessel pathology. Thromb Res. 2003; 109: 265–269.[CrossRef][Medline]
51. Slowik A, Dziedzic T, Turaj W, Pera J, Glodzik-Sobanska L, Szermer P, Malecki MT, Figlewicz DA, Szczudlik A. A2 alelle of GpIIIa gene is a risk factor for stroke caused by large-vessel disease in males. Stroke. 2004; 35: 1589–1593.
52. Lanni F, Santulli G, Izzo R, Rubattu S, Zanda B, Volpe M, Iaccarino G, Trimarco B. The Pl(A1/A2) polymorphism of glycoprotein IIIa and cerebrovascular events in hypertension: increased risk of ischemic stroke in high-risk patients. J Hypertens. 2007; 25: 551–556.[Medline]
53. van Goor ML, Gomez Garcia E, Brouwers GJ, Leebeek FW, Koudstaal PJ, Dippel DW. PLA1/A2 polymorphism of the platelet glycoprotein receptor IIb/IIIa in young patients with cryptogenic TIA or ischemic stroke. Thromb Res. 2002; 108: 63–65.[CrossRef][Medline]
54. Wagner KR, Giles WH, Johnson CJ, Ou CY, Bray PF, Goldschmidt-Clermont PJ, Croft JB, Brown VK, Stern BJ, Feeser BR, Buchholz DW, Earley CJ, Macko RF, McCarter RJ, Sloan MA, Stolley PD, Wityk RJ, Wozniak MA, Price TR, Kittner SJ. Platelet glycoprotein receptor IIIa polymorphism P1A2 and ischemic stroke risk: The stroke prevention in young women study. Stroke. 1998; 29: 581–585.
55. Elbaz A, Poirier O, Canaple S, Chedru F, Cambien F, Amarenco P. The association between the Val34Leu polymorphism in the factor XIII gene and brain infarction. Blood. 2000; 95: 586–591.
56. Slowik A, Dziedzic T, Pera J, Figlewicz DA, Szczudlik A. Coagulation factor XIII Vai34Leu polymorphism in patients with small vessel disease or primary intracerebral hemorrhage. Cerebrovasc Dis. 2005; 19: 165–170.[CrossRef][Medline]
57. Endler G, Funk M, Haering D, Lalouschek W, Lang W, Mirafzal M, Wagner O, Mannhalter C. Is the factor XIII 34Val/Leu polymorphism a protective factor for cerebrovascular disease? Br J Haematol. 2003; 120: 310–314.[CrossRef][Medline]
58. Catto AJ, Kohler HP, Bannan S, Stickland M, Carter A, Grant PJ. Factor XIII Val 34 Leu: a novel association with primary intracerebral hemorrhage. Stroke. 1998; 29: 813–816.
59. Chowdhury AH, Yokoyama T, Kokubo Y, Zaman MM, Haque A, Tanaka H. Apolipoprotein E genetic polymorphism and stroke subtypes in a Bangladeshi hospital-based study. J Epidemiol. 2001; 11: 131–138.[Medline]
60. Saidi S, Slamia LB, Ammou SB, Mahjoub T, Almawi WY. Association of apolipoprotein E gene polymorphism with ischemic stroke involving large-vessel disease and its relation to serum lipid levels. J Stroke Cerebrovasc Dis. 2007; 16: 160–166.[CrossRef][Medline]
61. Kessler C, Spitzer C, Stauske D, Mende S, Stadlmuller J, Walther R, Rettig R. The apolipoprotein E and beta-fibrinogen G/A-455 gene polymorphisms are associated with ischemic stroke involving large-vessel disease. Arterioscler Thromb Vasc Biol. 1997; 17: 2880–2884.
62. Kokubo Y, Chowdhury AH, Date C, Yokoyama T, Sobue H, Tanaka H. Age-dependent association of apolipoprotein E genotypes with stroke subtypes in a Japanese rural population. Stroke. 2000; 31: 1299–1306.
63. Cerrato P, Baima C, Grasso M, Lentini A, Bosco G, Cassader M, Gambino R, Cavallo Perin P, Pagano G, Fornengo P, Imperiale D, Bergamasco B, Bruno G. Apolipoprotein E polymorphism and stroke subtypes in an Italian cohort. Cerebrovasc Dis. 2005; 20: 264–269.[CrossRef][Medline]
64. Artieda M, Ganan A, Cenarro A, Garcia-Otin AL, Jerico I, Civeira F, Pocovi M. Association and linkage disequilibrium analyses of APOE polymorphisms in atherosclerosis. Dis Markers. 2008; 24: 65–72.[Medline]
65. Souza DR, Campos BF, Arruda EF, Yamamoto LJ, Trindade DM, Tognola WA. Influence of the polymorphism of apolipoprotein E in cerebral vascular disease. Arq Neuropsiquiatr. 2003; 61: 7–13.[Medline]
66. Slowik A, Iskra T, Turaj W, Hartwich J, Dembinska-Kiec A, Szczudlik A. LDL phenotype B and other lipid abnormalities in patients with large vessel disease and small vessel disease. J Neurol Sci. 2003; 214: 11–16.[CrossRef][Medline]
67. Sudlow C, Martinez Gonzalez NA, Kim J, Clark C. Does apolipoprotein E genotype influence the risk of ischemic stroke, intracerebral hemorrhage, or subarachnoid hemorrhage? Systematic review and meta-analyses of 31 studies among 5961 cases and 17,965 controls. Stroke. 2006; 37: 364–370.
68. Can Demirdogen B, Turkanoglu A, Bek S, Sanisoglu Y, Demirkaya S, Vural O, Arinc E, Adali O. Paraoxonase/arylesterase ratio, PON1 192Q/R polymorphism and PON1 status are associated with increased risk of ischemic stroke. Clin Biochem. 2008; 41: 1–9.[CrossRef][Medline]
69. Baum L, Ng HK, Woo KS, Tomlinson B, Rainer TH, Chen X, Cheung WS, Chan DK, Thomas GN, Tong CS, Wong KS. Paraoxonase 1 gene Q192R polymorphism affects stroke and myocardial infarction risk. Clin Biochem. 2006; 39: 191–195.[CrossRef][Medline]
70. Pasdar A, Ross-Adams H, Cumming A, Cheung J, Whalley L, St Clair D, MacLeod MJ. Paraoxonase gene polymorphisms and haplotype analysis in a stroke population. BMC Med Genet. 2006; 7: 28.[CrossRef][Medline]
71. Slowik A, Wloch D, Szermer P, Wolkow P, Malecki M, Pera J, Turaj W, Dziedzic T, Klimkowicz-Mrowiec A, Kopec G, Figlewicz DA, Szczudlik A. Paraoxonase 2 gene C311S polymorphism is associated with a risk of large vessel disease stroke in a Polish population. Cerebrovasc Dis. 2007; 23: 395–400.[CrossRef][Medline]
72. Li Z, Sun L, Zhang H, Liao Y, Wang D, Zhao B, Zhu Z, Zhao J, Ma A, Han Y, Wang Y, Shi Y, Ye J, Hui R. Elevated plasma homocysteine was associated with hemorrhagic and ischemic stroke, but methylenetetrahydrofolate reductase gene C677T polymorphism was a risk factor for thrombotic stroke: a multicenter case-control study in China. Stroke. 2003; 34: 2085–2090.
73. Choi BO, Kim NK, Kim SH, Kang MS, Lee S, Ahn JY, Kim OJ, Kim S, Oh D. Homozygous C677T mutation in the MTHFR gene as an independent risk factor for multiple small-artery occlusions. Thromb Res. 2003; 111: 39–44.[CrossRef][Medline]
74. Salooja N, Catto A, Carter A, Tudenham EG, Grant PJ. Methylene tetrahydrofolate reductase C677T genotype and stroke. Clin Lab Haematol. 1998; 20: 357–361.[CrossRef][Medline]
75. Linnebank M, Montenarh M, Kolsch H, Linnebank A, Schnez K, Schweichel D, Pohl C, Urbach H, Heun R, Harbrecht U, Klockgether T, Wullner U. Common genetic variants of homocysteine metabolism in ischemic stroke: a case-control study. Eur J Neurol. 2005; 12: 614–618.[CrossRef][Medline]
76. Markus HS, Ali N, Swaminathan R, Sankaralingam A, Molloy J, Powell J. A common polymorphism in the methylenetetrahydrofolate reductase gene, homocysteine, and ischemic cerebrovascular disease. Stroke. 1997; 28: 1739–1743.
77. Shen CD, Zhang WL, Sun K, Wang YB, Zhen YS, Hui RT. Interaction of genetic risk factors confers higher risk for thrombotic stroke in male Chinese: a multicenter case-control study. Ann Hum Genet. 2007; 71: 620–629.[CrossRef][Medline]
78. Dikmen M, Ozbabalik D, Gunes HV, Degirmenci I, Bal C, Ozdemir G, Basaran A. Acute stroke in relation to homocysteine and methylenetetrahydrofolate reductase gene polymorphisms. Acta Neurol Scand. 2006; 113: 307–314.[Medline]
79. Cronin S, Furie KL, Kelly PJ. Dose-related association of MTHFR 677T allele with risk of ischemic stroke: evidence from a cumulative meta-analysis. Stroke. 2005; 36: 1581–1587.
80. Gretarsdottir S, Sveinbjornsdottir S, Jonsson HH, Jakobsson F, Einarsdottir E, Agnarsson U, Shkolny D, Einarsson G, Gudjonsdottir HM, Valdimarsson EM, Einarsson OB, Thorgeirsson G, Hadzic R, Jonsdottir S, Reynisdottir ST, Bjarnadottir SM, Gudmundsdottir T, Gudlaugsdottir GJ, Gill R, Lindpaintner K, Sainz J, Hannesson HH, Sigurdsson GT, Frigge ML, Kong A, Gudnason V, Stefansson K, Gulcher JR. Localization of a susceptibility gene for common forms of stroke to 5q12. Am J Hum Genet. 2002; 70: 593–603.[CrossRef][Medline]
81. Gretarsdottir S, Thorleifsson G, Reynisdottir ST, Manolescu A, Jonsdottir S, Jonsdottir T, Gudmundsdottir T, Bjarnadottir SM, Einarsson OB, Gudjonsdottir HM, Hawkins M, Gudmundsson G, Gudmundsdottir H, Andrason H, Gudmundsdottir AS, Sigurdardottir M, Chou TT, Nahmias J, Goss S, Sveinbjornsdottir S, Valdimarsson EM, Jakobsson F, Agnarsson U, Gudnason V, Thorgeirsson G, Fingerle J, Gurney M, Gudbjartsson D, Frigge ML, Kong A, Stefansson K, Gulcher JR. The gene encoding phosphodiesterase 4D confers risk of ischemic stroke. Nat Genet. 2003; 35: 131–138.[CrossRef][Medline]
82. Helgadottir A, Manolescu A, Thorleifsson G, Gretarsdottir S, Jonsdottir H, Thorsteinsdottir U, Samani NJ, Gudmundsson G, Grant SF, Thorgeirsson G, Sveinbjornsdottir S, Valdimarsson EM, Matthiasson SE, Johannsson H, Gudmundsdottir O, Gurney ME, Sainz J, Thorhallsdottir M, Andresdottir M, Frigge ML, Topol EJ, Kong A, Gudnason V, Hakonarson H, Gulcher JR, Stefansson K. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet. 2004; 36: 233–239.[CrossRef][Medline]
83. Meschia JF, Brott TG, Brown RD Jr, Crook R, Worrall BB, Kissela B, Brown WM, Rich SS, Case LD, Evans EW, Hague S, Singleton A, Hardy J. Phosphodiesterase 4D and 5-lipoxygenase activating protein in ischemic stroke. Ann Neurol. 2005; 58: 351–361.[CrossRef][Medline]
84. Kuhlenbaumer G, Berger K, Huge A, Lange E, Kessler C, John U, Funke H, Nabavi DG, Stogbauer F, Ringelstein EB, Stoll M. Evaluation of single nucleotide polymorphisms in the phosphodiesterase 4D gene (PDE4D) and their association with ischaemic stroke in a large German cohort. J Neurol Neurosurg Psychiatry. 2006; 77: 521–524.
85. Woo D, Kaushal R, Kissela B, Sekar P, Wolujewicz M, Pal P, Alwell K, Haverbusch M, Ewing I, Miller R, Kleindorfer D, Flaherty M, Chakraborty R, Deka R, Broderick J. Association of phosphodiesterase 4D with ischemic stroke: a population-based case-control study. Stroke. 2006; 37: 371–376.
86. van Rijn MJ, Slooter AJ, Schut AF, Isaacs A, Aulchenko YS, Snijders PJ, Kappelle LJ, van Swieten JC, Oostra BA, van Duijn CM. Familial aggregation, the PDE4D gene, and ischemic stroke in a genetically isolated population. Neurology. 2005; 65: 1203–1209.
87. Kostulas K, Gretarsdottir S, Kostulas V, Manolescu A, Helgadottir A, Thorleifsson G, Gudmundsson LJ, Thorsteinsdottir U, Gulcher JR, Stefansson K, Hillert J. PDE4D and ALOX5AP genetic variants and risk for ischemic cerebrovascular disease in Sweden. J Neurol Sci. 2007; 263: 113–117.[CrossRef][Medline]
88. Bevan S, Dichgans M, Gschwendtner A, Kuhlenbaumer G, Ringelstein EB, Markus HS. Variation in the PDE4D gene and ischemic stroke risk: a systematic review and meta-analysis on 5200 cases and 6600 controls. Stroke. 2008; 39: 1966–1971.
89. Samani NJ, Erdmann J, Hall AS, Hengstenberg C, Mangino M, Mayer B, Dixon RJ, Meitinger T, Braund P, Wichmann HE, Barrett JH, Konig IR, Stevens SE, Szymczak S, Tregouet DA, Iles MM, Pahlke F, Pollard H, Lieb W, Cambien F, Fischer M, Ouwehand W, Blankenberg S, Balmforth AJ, Baessler A, Ball SG, Strom TM, Braenne I, Gieger C, Deloukas P, Tobin MD, Ziegler A, Thompson JR, Schunkert H. Genomewide association analysis of coronary artery disease. N Engl J Med. 2007; 357: 443–453.
90. Matarin M, Brown WM, Scholz S, Simon-Sanchez J, Fung HC, Hernandez D, Gibbs JR, De Vrieze FW, Crews C, Britton A, Langefeld CD, Brott TG, Brown RD Jr, Worrall BB, Frankel M, Silliman S, Case LD, Singleton A, Hardy JA, Rich SS, Meschia JF. A genome-wide genotyping study in patients with ischaemic stroke: initial analysis and data release. Lancet Neurol. 2007; 6: 414–420.[CrossRef][Medline]
91. Risch N, Merikangas K. The future of genetic studies of complex human diseases. Science. 1996; 273: 1516–1517.
92. Nilsson-Ardnor S, Janunger T, Wiklund PG, Lackovic K, Nilsson AK, Lindgren P, Escher SA, Stegmayr B, Asplund K, Holmberg D. Genome-wide linkage scan of common stroke in families from northern Sweden. Stroke. 2007; 38: 34–40.
93. Nilsson-Ardnor S, Wiklund PG, Lindgren P, Nilsson AK, Janunger T, Escher SA, Hallbeck B, Stegmayr B, Asplund K, Holmberg D. Linkage of ischemic stroke to the PDE4D region on 5Q in a Swedish population. Stroke. 2005; 36: 1666–1671.
94. Dichgans M, Markus HS. Genetic association studies in stroke: methodological issues and proposed standard criteria. Stroke. 2005; 36: 2027–2031.
95. Meschia JF. Addressing the heterogeneity of the ischemic stroke phenotype in human genetics research. Stroke. 2002; 33: 2770–2774.
96. Special report from the National Institute of Neurological Disorders and Stroke. Classification of cerebrovascular diseases III. Stroke. 1990; 21: 637–676.
97. Bamford J, Sandercock P, Dennis M, Burn J, Warlow C. Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet. 1991; 337: 1521–1526.[CrossRef][Medline]
98. O'Donnell CJ, Nabel EG. Cardiovascular genomics, personalized medicine, and the national heart, lung, and blood institute. Part I: The beginning of an era. Circ Cardiovasc Genet. 2008; 1: 51–57.
99. Manolio TA, Boerwinkle E, O'Donnell CJ, Wilson AF. Genetics of ultrasonographic carotid atherosclerosis. Arterioscler Thromb Vasc Biol. 2004; 24: 1567–1577.
100. Markus HS. Genes, endothelial function and cerebral small vessel disease in man. Exp Physiol. 2008; 93: 121–127.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||